Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 398 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
398 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with locally advanced/metastatic EGFR-mutant NSCLC or head and neck squamous cell carcinoma receive dose-escalated single-agent EPI-326. EPI-326 is an investigational tissue-selective bispecific antibody that binds EGFR and ITGB6 to promote internalization and lysosomal degradation of wild-type and mutant EGFR.
ClinicalTrials.gov ID: NCT07462377
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Open-label dose-escalation study of oral KST-6051, an investigational pan-KRAS inhibitor targeting both active and inactive KRAS conformations, in adults with locally advanced unresectable or metastatic KRAS-mutant solid tumors including NSCLC, pancreatic, colorectal, and other cancers. Patients must have progressed after or been intolerant of standard therapy, have ECOG 0-1 and measurable disease, with no prior/current RAS/KRAS inhibitor therapy or CNS metastases.
ClinicalTrials.gov ID: NCT07458347
TrialFetch AI summary: Adults with stage III/IV NSCLC and ECOG 0–1 after prior advanced-setting therapy including anti–PD-1/PD-L1, with secondary/acquired ICI resistance; later cohorts require prior platinum chemotherapy and docetaxel as third-line population. Treatment is IV THIO, an investigational telomere-targeting 6-thio-dG that induces telomere dysfunction/DNA damage in telomerase-positive tumor cells, given alone or sequenced before cemiplimab anti–PD-1.
ClinicalTrials.gov ID: NCT05208944
TrialFetch AI summary: Open-label dose-escalation/expansion study of oral TRI-611, a brain-penetrant ALK molecular glue degrader that promotes cereblon-mediated degradation of ALK fusion proteins, in adults with advanced measurable ALK-positive NSCLC. Cohorts include heavily ALK TKI–pretreated patients, including post-lorlatinib and post-neladalkib settings, as well as an ALK TKI–naïve cohort; stable CNS metastases are allowed.
ClinicalTrials.gov ID: NCT07491497
TrialFetch AI summary: Adults with advanced/metastatic PTK7-expressing solid tumors, including non-squamous EGFR-wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial carcinoma, receive HWK-007 IV every 3 weeks. HWK-007 is an investigational PTK7-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose escalation/expansion focused on safety, dose selection, pharmacokinetics, immunogenicity, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07444814
TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced c-Met–expressing solid tumors after standard therapy, with expansion cohorts emphasizing MET-amplified and/or c-Met–overexpressing nonsquamous NSCLC after prior platinum, immunotherapy, and targeted therapy when applicable. All patients receive CKD-703, a c-Met–targeted antibody–drug conjugate delivering the microtubule toxin MMAE.
ClinicalTrials.gov ID: NCT07439094
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326
TrialFetch AI summary: Eligible patients are adults with advanced NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine carcinoma, whose tumors express the NEO-201 antigen and who have progressed after standard therapies. Treatment consists of NEO-201 (a monoclonal antibody targeting tumor-associated O-glycans and CEACAM5/1 pathway) in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT03476681
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122